Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Soc Mass Spectrom ; 32(12): 2791-2802, 2021 Dec 01.
Article in English | MEDLINE | ID: mdl-34767352

ABSTRACT

A more complete and holistic view on host-microbe interactions is needed to understand the physiological and cellular barriers that affect the efficacy of drug treatments and allow the discovery and development of new therapeutics. Here, we developed a multimodal imaging approach combining histopathology with mass spectrometry imaging (MSI) and same section imaging mass cytometry (IMC) to study the effects of Salmonella Typhimurium infection in the liver of a mouse model using the S. Typhimurium strains SL3261 and SL1344. This approach enables correlation of tissue morphology and specific cell phenotypes with molecular images of tissue metabolism. IMC revealed a marked increase in immune cell markers and localization in immune aggregates in infected tissues. A correlative computational method (network analysis) was deployed to find metabolic features associated with infection and revealed metabolic clusters of acetyl carnitines, as well as phosphatidylcholine and phosphatidylethanolamine plasmalogen species, which could be associated with pro-inflammatory immune cell types. By developing an IMC marker for the detection of Salmonella LPS, we were further able to identify and characterize those cell types which contained S. Typhimurium.


Subject(s)
Mass Spectrometry/methods , Molecular Imaging/methods , Salmonella Infections/diagnostic imaging , Salmonella Infections/microbiology , Salmonella typhimurium/chemistry , Animals , Female , Mice , Mice, Inbred C57BL
2.
J Microbiol Methods ; 176: 106008, 2020 09.
Article in English | MEDLINE | ID: mdl-32707153

ABSTRACT

During the last two decades our understanding of the complex in vivo host-pathogen interactions has increased due to technical improvements and new research tools. The rapid advancement of molecular biology, flow cytometry and microscopy techniques, combined with mathematical modelling, have empowered in-depth studies of systemic bacterial infections across scales from single molecules, to cells, to organs and systems to reach the whole organism level. By tracking subpopulations of bacteria in vivo using molecular or fluorescent tags, it has been possible to reconstruct the spread of infection within and between organs, allowing unprecedented quantification of the effects of antimicrobial treatment and vaccination. This review illustrates recent advances in the study of heterogeneous traits of the infection process and illustrate approaches to investigate the reciprocal interactions between antimicrobial treatments, bacterial growth/death as well as inter- and intra-organ spread. We also discuss how vaccines impact the in vivo behaviour of bacteria and how these findings can guide vaccine design and rational antimicrobial treatment.


Subject(s)
Anti-Bacterial Agents/pharmacology , Host-Pathogen Interactions , Models, Biological , Salmonella Infections , Animals , Humans , Salmonella Infections/drug therapy , Salmonella Infections/microbiology , Spatio-Temporal Analysis
3.
PLoS One ; 14(3): e0213713, 2019.
Article in English | MEDLINE | ID: mdl-30861059

ABSTRACT

Tuberculosis (TB) is an infectious bacterial disease that kills approximately 1.3 million people every year. Despite global efforts to reduce both the incidence and mortality associated with TB, the emergence of drug resistant strains has slowed any progress made towards combating the spread of this deadly disease. The current TB drug regimen is inadequate, takes months to complete and poses significant challenges when administering to patients suffering from drug resistant TB. New treatments that are faster, simpler and more affordable are urgently required. Arguably, a good strategy to discover new drugs is to start with an old drug. Here, we have screened a library of 1200 FDA approved drugs from the Prestwick Chemical library using a GFP microplate assay. Drugs were screened against GFP expressing strains of Mycobacterium smegmatis and Mycobacterium bovis BCG as surrogates for Mycobacterium tuberculosis, the causative agent of TB in humans. We identified several classes of drugs that displayed antimycobacterial activity against both M. smegmatis and BCG, however each organism also displayed some selectivity towards certain drug classes. Variant analysis of whole genomes sequenced for resistant mutants raised to florfenicol, vanoxerine and pentamidine highlight new pathways that could be exploited in drug repurposing programmes.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antitubercular Agents/pharmacology , Drug Repositioning/methods , Mycobacterium tuberculosis/drug effects , Small Molecule Libraries/pharmacology , Tuberculosis, Multidrug-Resistant/drug therapy , Agar/chemistry , Anti-Infective Agents/pharmacology , Drug Design , Green Fluorescent Proteins/chemistry , Hep G2 Cells , Humans , Mutation , Mycobacterium bovis/drug effects , Mycobacterium smegmatis/drug effects , Pentamidine/pharmacology , Piperazines/pharmacology , Polymorphism, Single Nucleotide , Thiamphenicol/analogs & derivatives , Thiamphenicol/pharmacology , United States , United States Food and Drug Administration
SELECTION OF CITATIONS
SEARCH DETAIL
...